The results indicated that decreased expression of E-cadherin was significantly associated with FIGO stage (III–IV vs. I–II: HR = 3.74, 95% CI: 2.24–6.23), surgery (suboptimal vs. optimal, HR = 3.21, 95% CI: 1.19–8.67), residual tumor (≥ 1cm vs. < 1 cm, HR = 2.72, 95% CI: 1.99–3.72), and E-cadherin membranous (negative vs. positive, HR = 1.47, 95% CI: 1.01–2.14). The gene discussed is CDH1; the disease is neoplasm.